Seehofer D, Schoning W, Neuhaus P. Deceased donor liver transplantation. Chirurg. 2013;84:391–7.
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J. Hepatol. 2019;70:151–71.
Saidi RF, Hejazii Kenari SK. Challenges of organ shortage for transplantation: solutions and opportunities. Int J Organ Transpl. Med. 2014;5:87–96.
Potter KF, Cocchiola B, Quader MA. Donation after circulatory death: opportunities on the horizon. Curr Opin Anaesthesiol. 2021;34:168–72.
Croome KP, Taner CB. The Changing Landscapes in DCD Liver Transplantation. Curr. Transpl. Rep. 2020;7:194–204.
Forde JJ, Bhamidimarri KR. Management of Biliary Complications in Liver Transplant Recipients. Clin. Liver Dis. 2022;26:81–99.
Rodriguez-Peralvarez M, Rico-Juri JM, Tsochatzis E, Burra P, De la Mata M, Lerut J. Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. Transpl. Int. 2016;29:961–73.
Luo X, Nicoarä-Farcäu O, Magaz M, Betancourt F, Soy g, Baiges A, et al. Obstruction of the liver circulation. In: Taniguchi T, Lee S, editors. Cardio-Hepatology Connections Between Hepatic and Cardiovascular Disease: Academic Press; 2023. p. 65–92.
Lucas-Ruiz F, Mateo SV, Jover-Aguilar M, Alconchel F, Martinez-Alarcon L, de Torre-Minguela C, et al. Danger signals released during cold ischemia storage activate NLRP3 inflammasome in myeloid cells and influence early allograft function in liver transplantation. EBioMedicine. 2023;87:104419.
Villalba-Lopez F, Garcia-Bernal D, Mateo SV, Vidal-Correoso D, Jover-Aguilar M, Alconchel F, et al. Endothelial cell activation mediated by cold ischemia-released mitochondria is partially inhibited by defibrotide and impacts on early allograft function following liver transplantation. Biomed. Pharmacother. 2023;167:115529.
Barnett KC, Li S, Liang K, Ting JP. A 360 degrees view of the inflammasome: Mechanisms of activation, cell death, and diseases. Cell. 2023;186:2288–312.
Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell. 2002;10:417–26.
de Torre-Minguela C, Mesa Del Castillo P, Pelegrin P. The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases. Front Immunol. 2017;8:43.
Lucas-Ruiz F, Penin-Franch A, Pons JA, Ramirez P, Pelegrin P, Cuevas S, et al. Emerging Role of NLRP3 Inflammasome and Pyroptosis in Liver Transplantation. Int J Mol Sci. 2022;23:14396.
Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014;59:898–910.
Gaul S, Leszczynska A, Alegre F, Kaufmann B, Johnson CD, Adams LA, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J Hepatol. 2021;74:156–67.
Stutz A, Horvath GL, Monks BG, Latz E. ASC speck formation as a readout for inflammasome activation. Methods Mol Biol. 2013;1040:91–101.
Soriano-Teruel PM, Garcia-Lainez G, Marco-Salvador M, Pardo J, Arias M, DeFord C, et al. Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases. Cell Death Dis. 2021;12:1155.
Pareja E, Cortes M, Hervas D, Mir J, Valdivieso A, Castell JV, et al. A score model for the continuous grading of early allograft dysfunction severity. Liver Transpl. 2015;21:38–46.
Matesanz R, Dominguez-Gil B, Coll E, Mahillo B, Marazuela R. How Spain Reached 40 Deceased Organ Donors per Million Population. Am J Transpl. 2017;17:1447–54.
Siddiqui F, Al-Adwan Y, Subramanian J, Henry ML. Contemporary considerations in solid organ transplantation utilizing DCD donors. Transplant Rep. 2022;7:100118.
Danion J, Thuillier R, Allain G, Bruneval P, Tomasi J, Pinsard M, et al. Evaluation of Liver Quality after Circulatory Death Versus Brain Death: A Comparative Preclinical Pig Model Study. Int J Mol Sci. 2020;21: 9040.
Fu J, Wu H. Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation. Annu Rev. Immunol. 2023;41:301–16.
Xiao L, Magupalli VG, Wu H. Cryo-EM structures of the active NLRP3 inflammasome disc. Nature. 2023;613:595–600.
Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA. 2011;108:19725–30.
Faner R, Sobradillo P, Noguera A, Gomez C, Cruz T, Lopez-Giraldo A, et al. The inflammasome pathway in stable COPD and acute exacerbations. ERJ Open Res. 2016;2:00002–2016.
Hong BJ, Liu H, Wang ZH, Zhu YX, Su LY, Zhang MX, et al. Inflammasome activation involved in early inflammation reaction after liver transplantation. Immunol Lett. 2017;190:265–71.
Yu Y, Cheng Y, Pan Q, Zhang YJ, Jia DG, Liu YF. Effect of the Selective NLRP3 Inflammasome Inhibitor mcc950 on Transplantation Outcome in a Pig Liver Transplantation Model With Organs From Donors After Circulatory Death Preserved by Hypothermic Machine Perfusion. Transplantation. 2019;103:353–62.
Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16:407–20.
Ruan J, Xia S, Liu X, Lieberman J, Wu H. Cryo-EM structure of the gasdermin A3 membrane pore. Nature. 2018;557:62–7.
Kayagaki N, Kornfeld OS, Lee BL, Stowe IB, O’Rourke K, Li Q, et al. NINJ1 mediates plasma membrane rupture during lytic cell death. Nature. 2021;591:131–6.
Baroja-Mazo A, Martín-Sánchez F, Gomez AI, Martínez CM, Amores-Iniesta J, Compan V, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat. Immunol. 2014;15:738–48.
Sun P, Zhong J, Liao H, Loughran P, Mulla J, Fu G, et al. Hepatocytes Are Resistant to Cell Death From Canonical and Non-Canonical Inflammasome-Activated Pyroptosis. Cell Mol Gastroenterol Hepatol. 2022;13:739–57.
Feng YS, Tan ZX, Wang MM, Xing Y, Dong F, Zhang F. Inhibition of NLRP3 Inflammasome: A Prospective Target for the Treatment of Ischemic Stroke. Front Cell Neurosci. 2020;14:155.
Han PP, Han Y, Shen XY, Gao ZK, Bi X. NLRP3 inflammasome activation after ischemic stroke. Behav Brain Res. 2023;452:114578.
Zheng Y, Xu L, Dong N, Li F. NLRP3 inflammasome: The rising star in cardiovascular diseases. Front Cardiovasc Med. 2022;9:927061.
Wang Y, Huang H, He W, Zhang S, Liu M, Wu S. Association between serum NLRP3 and malignant brain edema in patients with acute ischemic stroke. BMC Neurol. 2021;21:341.
Cheng X, Zhao H, Wen X, Li G, Guo S, Zhang D. NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction. Life Sci. 2023;333:122185.
Toldo S, Mezzaroma E, Buckley LF, Potere N, Di Nisio M, Biondi-Zoccai G, et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharm. Ther. 2022;236:108053.
Pollara J, Edwards RW, Lin L, Bendersky VA, Brennan TV. Circulating mitochondria in deceased organ donors are associated with immune activation and early allograft dysfunction. JCI Insight. 2018;3:e121622.
Qiao J, Wu X, Luo Q, Wei G, Xu M, Wu Y, et al. NLRP3 regulates platelet integrin alphaIIbbeta3 outside-in signaling, hemostasis and arterial thrombosis. Haematologica. 2018;103:1568–76.
Martin-Sanchez F, Compan V, Penin-Franch A, Tapia-Abellan A, Gomez AI, Banos-Gregori MC, et al. ASC oligomer favors caspase-1CARD domain recruitment after intracellular potassium efflux. J Cell Biol. 2023;222:e202003053.
Tapia-Abellan A, Angosto-Bazarra D, Alarcon-Vila C, Banos MC, Hafner-Bratkovic I, Oliva B, et al. Sensing low intracellular potassium by NLRP3 results in a stable open structure that promotes inflammasome activation. Sci Adv. 2021;7:eabf4468.
Jimenez-Castro MB, Cornide-Petronio ME, Gracia-Sancho J, Peralta C. Inflammasome-Mediated Inflammation in Liver Ischemia-Reperfusion Injury. Cells. 2019;8:1131.
van Beekum CJ, Vilz TO, Glowka TR, von Websky MW, Kalff JC, Manekeller S. Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives. Ann. Transpl. 2021;26:e931664.
Dengu F, Abbas SH, Ebeling G, Nasralla D. Normothermic Machine Perfusion (NMP) of the Liver as a Platform for Therapeutic Interventions during Ex-Vivo Liver Preservation: A Review. J Clin Med. 2020;9.
Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA. Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark. Insights. 2010;5:9–20.
O’Hurley G, Sjostedt E, Rahman A, Li B, Kampf C, Ponten F, et al. Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol. Oncol. 2014;8:783–98.
Dunstan RW, Wharton KA Jr, Quigley C, Lowe A. The use of immunohistochemistry for biomarker assessment-can it compete with other technologies? Toxicol. Pathol. 2011;39:988–1002.
Nistor A, Watson PH, Pettigrew N, Tabiti K, Dawson A, Myal Y. Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin. Pathol. 2006;6:2.
Hessheimer AJ, Coll E, Torres F, Ruiz P, Gastaca M, Rivas JI, et al. Normothermic regional perfusion vs. super-rapid recovery in controlled donation after circulatory death liver transplantation. J. Hepatol. 2019;70:658–65.
Watson CJE, Hunt F, Messer S, Currie I, Large S, Sutherland A, et al. In situ normothermic perfusion of livers in controlled circulatory death donation may prevent ischemic cholangiopathy and improve graft survival. Am. J. Transpl. 2019;19:1745–58.
Hessheimer AJ, de la Rosa G, Gastaca M, Ruiz P, Otero A, Gomez M, et al. Abdominal normothermic regional perfusion in controlled donation after circulatory determination of death liver transplantation: Outcomes and risk factors for graft loss. Am J Transplant. 2021.
Cascales-Campos PA, Ferreras D, Alconchel F, Febrero B, Royo-Villanova M, Martinez M, et al. Controlled donation after circulatory death up to 80 years for liver transplantation: Pushing the limit again. Am J Transpl. 2020;20:204–12.
Ormonde DG, de Boer WB, Kierath A, Bell R, Shilkin KB, House AK, et al. Banff schema for grading liver allograft rejection: utility in clinical practice. Liver Transpl Surg. 1999;5:261–8.
Barbera-Cremades M, Baroja-Mazo A, Gomez AI, Machado F, Di Virgilio F, Pelegrin P. P2X7 receptor-stimulation causes fever via PGE2 and IL-1beta release. FASEB J. 2012;26:2951–62.
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–82.
Baroja-Mazo A, Compan V, Martin-Sanchez F, Tapia-Abellan A, Couillin I, Pelegrin P. Early endosome autoantigen 1 regulates IL-1beta release upon caspase-1 activation independently of gasdermin D membrane permeabilization. Sci Rep. 2019;9:5788.
Kunselman AR. A brief overview of pilot studies and their sample size justification. Fertil Steril. 2024.
